<DOC>
	<DOCNO>NCT00888082</DOCNO>
	<brief_summary>Primary objective study determine effectiveness goserelin acetate ( Zoladex ) preserve ovarian function premenopausal woman undergo adjuvant chemotherapy primary invasive breast cancer document persistence resumption regular menses via menstrual history , serum FSH E2 measurement . The secondary objective study follow : To investigate impact treatment chemotherapy without goserelin acetate ( i.e . impact expectation ovarian function preservation ) participant ' quality life ( QOL ) FACT-ES scale , compare safety tolerability study drug two treatment group evaluation adverse event .</brief_summary>
	<brief_title>Protection Ovarian Function With Goserelin Acetate Premenopausal Early Breast Cancer Patients With Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Pathologically confirm invasive breast carcinoma Candidates adjuvant chemotherapy primary breast cancer Premenopausal , verify chemotherapy begin satisfy cyclic vaginal bleeding appropriate hormone level Previous systemic chemotherapy Pregnancy Stage IV breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>breast cancer</keyword>
	<keyword>goserelin acetate</keyword>
	<keyword>ovarian function</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Primary invasive breast cancer</keyword>
</DOC>